Reply to "Ivermectin Treatment May Improve the Prognosis of Patients With COVID-19".
作者信息
Khan Md Saiful Islam, Khan Md Sakirul Islam, Debnath Chitto Ranjan, Nath Progga Nanda, Mahtab Mamun Al, Nabeka Hiroaki, Matsuda Seiji, Akbar Sheikh Mohammad Fazle
机构信息
COVID-19 Management Team, Mymensingh Medical College and Hospital, Mymensingh 2207, Bangladesh.
Department of Anatomy and Embryology, Ehime University Graduate School of Medicine, Toon, Ehime 791-0295, Japan.
出版信息
Arch Bronconeumol. 2021 Apr;57:65-66. doi: 10.1016/j.arbres.2020.12.013. Epub 2020 Dec 31.
Abstract
摘要
相似文献
1
Reply to "Ivermectin Treatment May Improve the Prognosis of Patients With COVID-19".对《伊维菌素治疗可能改善COVID-19患者预后》的回复
Arch Bronconeumol. 2021 Apr;57:65-66. doi: 10.1016/j.arbres.2020.12.013. Epub 2020 Dec 31.
2
Ivermectin Treatment May Improve the Prognosis of Patients With COVID-19.伊维菌素治疗可能改善新冠病毒肺炎患者的预后。
Arch Bronconeumol (Engl Ed). 2020 Dec;56(12):828-830. doi: 10.1016/j.arbr.2020.08.011. Epub 2020 Dec 14.
3
Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): A single-centre randomized, placebo-controlled trial.单剂量口服伊维菌素治疗轻中度 COVID-19（RIVET-COV）：一项单中心随机、安慰剂对照试验。
J Infect Chemother. 2021 Dec;27(12):1743-1749. doi: 10.1016/j.jiac.2021.08.021. Epub 2021 Aug 25.
4
Ivermectin treatment for infection in patients with COVID-19.伊维菌素治疗新型冠状病毒肺炎患者的感染情况。
Can Commun Dis Rep. 2021 Jul 8;47(7-8):316-321. doi: 10.14745/ccdr.v47i78a04.
5
Self-prescribed Ivermectin use is associated with a lower rate of seroconversion in health care workers diagnosed with COVID, in a dose-dependent response.自我处方伊维菌素的使用与 COVID 确诊医护人员的血清转化率降低有关，且呈剂量依赖性反应。
Braz J Infect Dis. 2021 Jul-Aug;25(4):101603. doi: 10.1016/j.bjid.2021.101603. Epub 2021 Aug 12.
6
Prophylactic Role of Ivermectin in Severe Acute Respiratory Syndrome Coronavirus 2 Infection Among Healthcare Workers.伊维菌素在医护人员严重急性呼吸综合征冠状病毒2感染中的预防作用
Cureus. 2021 Aug 5;13(8):e16897. doi: 10.7759/cureus.16897. eCollection 2021 Aug.
7
A five-day course of ivermectin may reduce the duration of COVID-19 illness.为期五天的伊维菌素疗程可能会缩短新冠病毒疾病的病程。
Int J Infect Dis. 2021 Sep;110:93-94. doi: 10.1016/j.ijid.2021.07.050. Epub 2021 Jul 26.
8
A COVID-19 prophylaxis? Lower incidence associated with prophylactic administration of ivermectin.一种 COVID-19 预防药物？伊维菌素预防性给药与较低的发病率相关。
Int J Antimicrob Agents. 2021 Jan;57(1):106248. doi: 10.1016/j.ijantimicag.2020.106248. Epub 2020 Nov 28.
9
[Potential interactions with ivermectin as adjuvant therapy for refractory epilepsy. Reply].[作为难治性癫痫辅助治疗的伊维菌素的潜在相互作用。回复]
Rev Neurol. 2018 Apr 1;66(7):251-252.
10
Ivermectin & COVID-19: Let's keep a One Health perspective.伊维菌素与新冠病毒：让我们秉持“同一健康”视角。
Sustain Chem Pharm. 2021 Jun;21:100438. doi: 10.1016/j.scp.2021.100438. Epub 2021 Apr 18.
本文引用的文献
1
Ivermectin Treatment May Improve the Prognosis of Patients With COVID-19.伊维菌素治疗可能改善新冠病毒肺炎患者的预后。
Arch Bronconeumol (Engl Ed). 2020 Dec;56(12):828-830. doi: 10.1016/j.arbr.2020.08.011. Epub 2020 Dec 14.
2
Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.用于治疗新冠肺炎的抗病毒药物 repurposed - 世界卫生组织团结试验中期结果
N Engl J Med. 2021 Feb 11;384(6):497-511. doi: 10.1056/NEJMoa2023184. Epub 2020 Dec 2.
3
Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia.一项关于使用法匹拉韦联合吸入用干扰素β-1b 治疗中重度 COVID-19 肺炎住院患者的随机对照开放标签试验。
Int J Infect Dis. 2021 Jan;102:538-543. doi: 10.1016/j.ijid.2020.11.008. Epub 2020 Nov 9.
4
Binding mechanism and structural insights into the identified protein target of COVID-19 and importin-α with effective drug ivermectin.新型冠状病毒与伊维菌素有效药物的识别蛋白靶标和 Importin-α 的结合机制和结构见解。
J Biomol Struct Dyn. 2022 Mar;40(5):2217-2226. doi: 10.1080/07391102.2020.1839564. Epub 2020 Oct 28.
5
Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019: The Ivermectin in COVID Nineteen Study.使用伊维菌素与 COVID-19 住院患者的死亡率降低相关：COVID-19 中的伊维菌素研究。
Chest. 2021 Jan;159(1):85-92. doi: 10.1016/j.chest.2020.10.009. Epub 2020 Oct 13.
6
Development of a Minimal Physiologically-Based Pharmacokinetic Model to Simulate Lung Exposure in Humans Following Oral Administration of Ivermectin for COVID-19 Drug Repurposing.开发一种最小生理基于药代动力学模型，以模拟新冠肺炎药物再利用中经口给予伊维菌素后人体肺部的暴露情况。
J Pharm Sci. 2020 Dec;109(12):3574-3578. doi: 10.1016/j.xphs.2020.08.024. Epub 2020 Sep 4.
7
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.瑞德西韦对比标准治疗对 11 天内中症 COVID-19 患者临床状态的影响：一项随机临床试验。
JAMA. 2020 Sep 15;324(11):1048-1057. doi: 10.1001/jama.2020.16349.
8
Real-life Management Strategy of COVID-19 Patients in Bangladesh with No Death: An Observational and Cohort Study.孟加拉国无死亡新冠患者的现实管理策略：一项观察性队列研究
Euroasian J Hepatogastroenterol. 2020 Jan-Jun;10(1):31-35. doi: 10.5005/jp-journals-10018-1316.
9
Treatment of COVID-19 Patients at a Medical College Hospital in Bangladesh.孟加拉国一所医学院附属医院对新冠肺炎患者的治疗
Euroasian J Hepatogastroenterol. 2020 Jan-Jun;10(1):27-30. doi: 10.5005/jp-journals-10018-1317.
10
Dexamethasone in Hospitalized Patients with Covid-19.地塞米松在 COVID-19 住院患者中的应用。
N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17.
Zotero 插件